Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inoviq Ltd ( (AU:IIQ) ) has shared an announcement.
INOVIQ Limited has successfully completed the issuance of over 27 million fully paid ordinary shares to institutional and sophisticated investors. Additionally, the company has launched a Share Purchase Plan (SPP) offering existing shareholders in Australia and New Zealand the opportunity to purchase new shares at $0.35 each, aiming to raise up to $2 million. This initiative is part of INOVIQ’s strategy to enhance its financial position and support its ongoing advancements in cancer diagnostics and therapeutics.
The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology, focusing on advancing next-generation diagnostics and therapeutics to transform cancer care. The company’s product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program for solid tumors.
Average Trading Volume: 109,638
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$41.3M
See more data about IIQ stock on TipRanks’ Stock Analysis page.